Computer-Aided Imaging Analysis of Probe-Based Confocal Laser Endomicroscopy With Molecular Labeling and Gene Expression Identifies Markers of Response to Biological Therapy in IBD Patients: The Endo-Omics Study
Inflammatory Bowel Diseases · 01.09.2023 · 29 (9) · 1409-1420
DOI: 10.1093/ibd/izac233 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 15.11.2022. Verfasst von Marietta Iacucci und 17 weiteren Autor:innen. Beteiligte Einrichtung: National Institute for Health Research Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, UK. Hauptthemen laut MEDLINE: Crohn Disease, Inflammatory Bowel Diseases, Colitis, Ulcerative, Biological Products. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
We aimed to predict response to biologics in inflammatory bowel disease (IBD) using computerized image analysis of probe confocal laser endomicroscopy (pCLE) in vivo and assess the binding of fluorescent-labeled biologics ex vivo. Additionally, we investigated genes predictive of anti-tumor necrosis factor (TNF) response.
Methods
Twenty-nine patients (15 with Crohn’s disease [CD], 14 with ulcerative colitis [UC]) underwent colonoscopy with pCLE before and 12 to 14 weeks after starting anti-TNF or anti-integrin α4β7 therapy. Biopsies were taken for fluorescein isothiocyanate–labeled infliximab and vedolizumab staining and gene expression analysis. Computer-aided quantitative image analysis of pCLE was performed. Differentially expressed genes predictive of response were determined and validated in a public cohort.
Results
In vivo, vessel tortuosity, crypt morphology, and fluorescein leakage predicted response in UC (area under the receiver-operating characteristic curve [AUROC], 0.93; accuracy 85%, positive predictive value [PPV] 89%; negative predictive value [NPV] 75%) and CD (AUROC, 0.79; accuracy 80%; PPV 75%; NPV 83%) patients. Ex vivo, increased binding of labeled biologic at baseline predicted response in UC (UC) (AUROC, 83%; accuracy 77%; PPV 89%; NPV 50%) but not in Crohn’s disease (AUROC 58%). A total of 325 differentially expressed genes distinguished responders from nonresponders, 86 of which fell within the most enriched pathways. A panel including ACTN1, CXCL6, LAMA4, EMILIN1, CRIP2, CXCL13, and MAPKAPK2 showed good prediction of anti-TNF response (AUROC >0.7).
Conclusions
Higher mucosal binding of the drug target is associated with response to therapy in UC. In vivo, mucosal and microvascular changes detected by pCLE are associated with response to biologics in inflammatory bowel disease. Anti-TNF–responsive UC patients have a less inflamed and fibrotic state pretreatment. Chemotactic pathways involving CXCL6 or CXCL13 may be novel targets for therapy in nonresponders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Institute for Health Research Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, UK.
- Gastroenterology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
- National Institute for Health Research Surgical Reconstruction, Queen Elizabeth Hospital Birmingham, Birmingham, UK.
- Department of Information Engineering, University of Padova, Padova, Italy.
ORCID-Profile: Marietta Iacucci, Animesh Acharjee, Olga M Nardone, Ren Mao, Tommaso Lorenzo Parigi, Subrata Ghosh
Zitieren
APA
Iacucci, M., Jeffery, L., Acharjee, A., Grisan, E., Buda, A., Nardone, O. M., Smith, S. C. L., Labarile, N., Zardo, D., Ungar, B., Hunter, S., Mao, R., Cannatelli, R., Shivaji, U. N., Parigi, T. L., Reynolds, G. M., Gkoutos, G. V., & Ghosh, S. (2023). Computer-Aided Imaging Analysis of Probe-Based Confocal Laser Endomicroscopy With Molecular Labeling and Gene Expression Identifies Markers of Response to Biological Therapy in IBD Patients: The Endo-Omics Study. Inflammatory Bowel Diseases, 29(9), 1409-1420. https://doi.org/10.1093/ibd/izac233
Vancouver
Iacucci M, Jeffery L, Acharjee A, Grisan E, Buda A, Nardone OM, et al. Computer-Aided Imaging Analysis of Probe-Based Confocal Laser Endomicroscopy With Molecular Labeling and Gene Expression Identifies Markers of Response to Biological Therapy in IBD Patients: The Endo-Omics Study. Inflammatory Bowel Diseases. 2023;29(9):1409-1420. doi:10.1093/ibd/izac233
BibTeX
@article{Iacucci2023,
author = {Iacucci, Marietta and Jeffery, Louisa and Acharjee, Animesh and Grisan, Enrico and Buda, Andrea and Nardone, Olga M and Smith, Samuel C L and Labarile, Nunzia and Zardo, Davide and Ungar, Bella and Hunter, Stuart and Mao, Ren and Cannatelli, Rosanna and Shivaji, Uday N and Parigi, Tommaso Lorenzo and Reynolds, Gary M and Gkoutos, Georgios V and Ghosh, Subrata},
title = {Computer-Aided Imaging Analysis of Probe-Based Confocal Laser Endomicroscopy With Molecular Labeling and Gene Expression Identifies Markers of Response to Biological Therapy in IBD Patients: The Endo-Omics Study},
journal = {Inflammatory Bowel Diseases},
year = {2023},
volume = {29},
number = {9},
pages = {1409--1420},
doi = {10.1093/ibd/izac233}
}
EUVIMED